Literature DB >> 23923075

Expression of soluble Fas and soluble FasL in human nucleus pulposus cells.

Zhen Sun1, Zhong-Yuan Wan, Zhi-Heng Liu, Yun-Shan Guo, Jun-Bin Yin, Chun-Guang Duan, Yang Gao, Tao Li, Hai-Qiang Wang, Zhuo-Jing Luo.   

Abstract

The study aimed for addressing the expression of soluble Fas (sFas) and soluble Fas Ligand (sFasL) in human nucleus pulposus (NP) and its attendant relationship with disc degeneration. Human NP samples were collected from patients with disc degeneration and cadavers as degenerate and normal groups, respectively. Subsequently, NP cells were cultured in monolayer. ELISA was performed to identify the expression levels of sFas and sFasL in the supernatant of NP cell cultures in vitro. Quantitative real-time PCR was used to detect the expression of sFas and sFasL in human NP cells in mRNA solution. The study comprised 12 degenerate and 8 normal cadaveric NP samples. The concentration value of sFas in the supernatant was significantly higher from degenerate NP than that from normal NP at each time point. In contrast, sFasL was significantly lower at each time point. Moreover, the expression of sFas and sFasL reached the peak at various early stages of cell cultures and decreased thereafter. Furthermore, the mRNA level of Fas in degenerate NP cells was significantly higher than that in normal cells; whereas FasL showed an opposite pattern. The study is the first addressing the expression of sFas and sFasL in human NP cell cultures. Moreover, the expression of sFas and sFasL varies with culture time in vitro with different levels in degenerate and normal settings. These findings indicate that sFas and sFasL might play a role in intervertebral disc degeneration.

Entities:  

Keywords:  Intervertebral disc; immune privilege; nucleus pulposus; soluble Fas; soluble FasL

Mesh:

Substances:

Year:  2013        PMID: 23923075      PMCID: PMC3726972     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  Expression of Fas receptor on disc cells in herniated lumbar disc tissue.

Authors:  J B Park; K W Kim; C W Han; H Chang
Journal:  Spine (Phila Pa 1976)       Date:  2001-01-15       Impact factor: 3.468

Review 2.  Immune cascades in human intervertebral disc: the pros and cons.

Authors:  Zhen Sun; Ming Zhang; Xu-Hong Zhao; Zhi-Heng Liu; Yang Gao; Dino Samartzis; Hai-Qiang Wang; Zhuo-Jing Luo
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

3.  Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family.

Authors:  T Suda; T Takahashi; P Golstein; S Nagata
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

4.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

Review 5.  Anatomy of intervertebral disc and pathophysiology of herniated disc disease.

Authors:  S K Mirza; A A White
Journal:  J Clin Laser Med Surg       Date:  1995-06

6.  A role for CD95 ligand in preventing graft rejection.

Authors:  D Bellgrau; D Gold; H Selawry; J Moore; A Franzusoff; R C Duke
Journal:  Nature       Date:  1995-10-19       Impact factor: 49.962

7.  Downregulation of Fas ligand by shedding.

Authors:  M Tanaka; T Itai; M Adachi; S Nagata
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

8.  Fas ligand exists on intervertebral disc cells: a potential molecular mechanism for immune privilege of the disc.

Authors:  Toru Takada; Kotaro Nishida; Minoru Doita; Masahiro Kurosaka
Journal:  Spine (Phila Pa 1976)       Date:  2002-07-15       Impact factor: 3.468

9.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.

Authors:  J Cheng; T Zhou; C Liu; J P Shapiro; M J Brauer; M C Kiefer; P J Barr; J D Mountz
Journal:  Science       Date:  1994-03-25       Impact factor: 47.728

10.  Expression of the functional soluble form of human fas ligand in activated lymphocytes.

Authors:  M Tanaka; T Suda; T Takahashi; S Nagata
Journal:  EMBO J       Date:  1995-03-15       Impact factor: 11.598

View more
  7 in total

1.  FasL on human nucleus pulposus cells prevents angiogenesis in the disc by inducing Fas-mediated apoptosis of vascular endothelial cells.

Authors:  Zhen Sun; Zhong-Yuan Wan; Yun-Shan Guo; Hai-Qiang Wang; Zhuo-Jing Luo
Journal:  Int J Clin Exp Pathol       Date:  2013-10-15

2.  [Association of FasL-844T/C gene polymorphism with FasL expression in the nucleus pulposus of degenerative lumbar intervertebral discs].

Authors:  Zheng-Ming Sun; Pengmaojiacuo Pengmaojiacuo; Hong-Hai Xu; Yan-Hai Chang; Xue-Yuan Wu; Xiang-Hui Dong; Ming Ling
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-07-20

Review 3.  Clarifying the nomenclature of intervertebral disc degeneration and displacement: from bench to bedside.

Authors:  Hai-Qiang Wang; Dino Samartzis
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

4.  Interplay between low plasma RANKL and VDR-FokI polymorphism in lumbar disc herniation independently from age, body mass, and environmental factors: a case-control study in the Italian population.

Authors:  Veronica Sansoni; Silvia Perego; Alessandra Colombini; Giuseppe Banfi; Marco Brayda-Bruno; Giovanni Lombardi
Journal:  Eur Spine J       Date:  2015-08-11       Impact factor: 3.134

5.  Genome-Wide Identification of Long Noncoding RNAs in Human Intervertebral Disc Degeneration by RNA Sequencing.

Authors:  Bo Zhao; Minjuan Lu; Dong Wang; Haopeng Li; Xijing He
Journal:  Biomed Res Int       Date:  2016-12-20       Impact factor: 3.411

6.  Aberrantly expressed long noncoding RNAs in human intervertebral disc degeneration: a microarray related study.

Authors:  Zhong-Yuan Wan; Fang Song; Zhen Sun; Yu-Fei Chen; Wei-Lin Zhang; Dino Samartzis; Chi-Jiao Ma; Lu Che; Xu Liu; M-Azam Ali; Hai-Qiang Wang; Zhuo-Jing Luo
Journal:  Arthritis Res Ther       Date:  2014-10-04       Impact factor: 5.156

Review 7.  Targeted therapy for intervertebral disc degeneration: inhibiting apoptosis is a promising treatment strategy.

Authors:  Xiao-Bo Zhang; Yi-Cun Hu; Peng Cheng; Hai-Yu Zhou; Xiang-Yi Chen; Ding Wu; Rui-Hao Zhang; De-Chen Yu; Xi-Dan Gao; Jin-Tao Shi; Kai Zhang; Shao-Long Li; Peng-Jie Song; Ke-Ping Wang
Journal:  Int J Med Sci       Date:  2021-05-27       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.